Philipp Kaiser from Warburg Research retains his positive opinion on the stock with a Buy rating. The target price has been revised downwards and is now set at EUR 11.70 as compared to EUR 14.60. | February 15, 2023
Analyst Philipp Kaiser from Warburg Research research considers the stock attractive and recommends it with a Buy rating. The target price is decreased from EUR 14.80 to EUR 14.30. | January 13, 2023
LUND, Sweden, Nov. 16, 2022 /PRNewswire/ Immunovia AB (NASDAQ: IMMNOV) announces today that Philipp Mathieu, CEO of Immunovia, has purchased 150000 warrants of the 2022/2026 scheme for approximately